Shi Hu received an M.D. and a Ph.D. in Cancer Immunology from Second Military Medical University, Shanghai, China. Since 2015, Dr. Hu leads a research laboratory as Professor of Biomedical Engineering in the Department of Biophysics, at second military medical university with a faculty position. His laboratory is interested in the development of novel antibody or cell based therapeutics. Dr. Hu’s research is currently supported by the National Natural Science Foundation of China.
Research Area and Skills
Recognize this scientist’s Expertise for their contribution in your research
molecular targeted therapeutics 0 cancer treatment 0
Hello everyone! I have successfully joined Cloud Scientist program！ I received an M.D. and a Ph.D. in Cancer Immunology from Second Military Medical University, Shanghai, China. Since 2015, I lead a research laboratory as Professor of Biomedical Engineering in the Department of ...Learn More
Lei Changhai, et al; and Hu Shi*; Neutralization of SARS CoV-2 spike pseudotyped virus by 2 recombinant ACE2-Ig, Nature Communications 11, 2070 (2020)
Fu, Wenyan; et al; and Hu, Shi*; CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nature Communications, 2019, 10: 0-4355.
Fu Wenyan, et a; and Hu, Shi*; EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency, Clinical Cancer Research, 2019, 25(9): 2835-2847.
Liu, Shuowu, et al, and Hu, Shi*; Treatment of murine lupus with TIGIT-Ig. Clinical immunology 203 (2019): 72-80.
Li, Tian, et al, and Hu, Shi*; Targeting RyR2 with a phosphorylation site–specific nanobody reverses dysfunction of failing cardiomyocytes in rats. The FASEB Journal 33.6 (2019): 7467-7478
Tian Li, et al, and Shi Hu*; Cardiac adenovirus-associated viral Presenilin 1 gene delivery protects the left ventricular function of the heart via regulating RyR2 function in post-ischemic heart failure. Journal of Drug Targeting 03/2018.
Shi Hu*, et al; Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency. Science Translational Medicine 03/2017; 9(380).
Shi Hu*, et al; Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. Cancer letters 08/2016; 382(1).
Shi Hu*, et al; Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer Research 11/2014; 75(1).